REG - Arecor Therapeutics - ARECOGRANTED PATENT IN JAPAN AND SOUTH KOREA

Arecor TherapeuticsAnnouncement

22/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221122:nRSV1358Ha&default-theme=true

RNS Number : 1358H  Arecor Therapeutics PLC  22 November 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR GRANTED KEY PATENT IN JAPAN AND SOUTH KOREA TO PROTECT PROPRIETARY
INSULIN PRODUCTS AT247 AND AT278

 

The granted patents further strengthen the Group's extensive patent portfolio
protecting its proprietary Arestat™ technology and diabetes product
portfolio

 

Cambridge, UK, 22 November 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
is pleased to announce that the Japan Patent Office has granted a patent
(JP7145849) protecting novel formulations of the Group's proprietary insulin
products, AT247 and AT278. The same patent has also been granted in South
Korea.

 

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "Enabled by our
Arestat(TM) technology platform we have two proprietary insulin product
candidates within clinical development based on novel formulations of existing
insulin that have the potential to bring significant patients to people living
with diabetes.  We have demonstrated in Phase I clinical studies that we have
both an ultra-rapid acting insulin (AT247) with the potential to enable an
artificial pancreas system which would be transformative for patients, as well
as an ultra-concentrated ultra-rapid acting insulin (AT278) which has the
potential to become the gold standard insulin for the growing population of
people with diabetes with high daily insulin needs. With these very promising
profiles, we will be looking to gain market share within the existing >$6bn
prandial global insulin market and, as such, intellectual property protection
of AT247 and AT278 is critical.  The grant of this key patent protecting
AT247 and AT278 in Japan and South Korea, following on from the US patent
granted earlier this year within our insulin IP portfolio, marks an important
milestone in our comprehensive IP strategy as we continue to maximise the IP
protection for our insulin products."

 

The Arestat™ technology enables superior product profiles across a broad
range of pharmaceuticals. Arecor leverages the technology to develop its own
portfolio of superior proprietary products in diabetes and other
indications.  In addition, Arecor partners with leading pharmaceutical and
biotechnology companies to deliver enhanced formulations of their therapeutic
products under a technology licensing model.

 

 

 

Arecor has invested in building a strong patent portfolio to protect the
Arestat™ technology platform and the proprietary pipeline products. The
Group's intellectual property (IP) portfolio currently comprises 36 patent
families, including >50 granted patents in Europe, the US and in other key
territories.  As part of this strategy, Arecor has robust IP that protects
the novel compositions of AT247 and AT278, as well as their specific
properties and methods of use. Arecor's strategy is to generate a fortress of
both narrow and broad interrelated IP rights that cover the key features of
these products. The grant of these patents marks an important milestone within
the Group's comprehensive proprietary insulin product IP strategy.

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

 

Notes to Editors

 

About AT247

AT247 is Arecor's ultra-rapid insulin that has been demonstrated in Phase I
clinical studies to accelerate significantly insulin absorption post
injection, and thus enable more effective management of blood glucose levels
for people living with diabetes, particularly around difficult to manage
mealtimes.  Such ultra-rapid acting insulin may facilitate an automated
insulin delivery via a fully closed loop artificial pancreas, a potentially
life changing treatment option for people living with diabetes.

 

About AT278

AT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin that
has been designed to accelerate the absorption of insulin post injection, even
when delivered at a high concentration, and hence via a lower injection
volume. Currently, there are no concentrated (>200 U/mL) rapid acting
insulin products on the market and therefore AT278 has the potential to be the
first such product available to patients. It has the potential to enable more
effective management of blood glucose levels to the increasing number of
people with diabetes with high daily insulin requirements (>200 units/day)
whilst maintaining the convenience and compliance benefits of being able to
deliver these high insulin doses in a lower injection volume via a single
injection. In addition, a truly rapid acting concentrated insulin is also a
critical step towards the advancement and miniaturisation of the next
generation of insulin delivery devices.

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFFFLELLFIF